For oral NAD⁺ precursors, the short-term safety evidence is real and reassuring as far as it goes: dedicated trials have given people NR and NMN at high doses for weeks and found no moderate or severe adverse events. For injected and infused NAD⁺, there is no comparable evidence, and that gap is a risk you carry rather than a clean bill of health.
The more useful question is not “is it safe” but “safe as established by what, and over how long.” That is what this page is about; what the safety trials actually reported is the companion page with the findings themselves.
The shape of the evidence, not just its result
The safety trials in this category are small and short. The NR-SAFE trial randomized 20 people with Parkinson’s disease 1:1 to nicotinamide riboside 1,500 mg twice daily (n = 10) or placebo (n = 10) for four weeks; all 20 completed, there were no moderate or severe adverse events and no significant difference in mild ones, and blood NAD⁺ rose up to five-fold. Its own background notes that doses above 2,000 mg daily had not previously been tested in humans, and it reported a slight initial rise in serum homocysteine among NR recipients [1]. A separate study gave 1,250 mg of β-NMN once daily for up to four weeks to 31 healthy adults aged 20 to 65 and found no severe adverse events over the study period [2].
Those are the right studies to have run. They are also dozens of people for a month. A trial of that size can detect a side effect that affects one person in ten; it cannot detect one that affects one in a thousand, and it says nothing at all about taking something every day for five years. When a seller writes “clinically proven safe”, that is the box they are describing, whether they know it or not.
Compounded is not approved, and the difference is the whole point
Injectable and intravenous NAD⁺ are compounded preparations. That means they are not FDA-approved and are not reviewed by the FDA for safety, efficacy or quality before they are dispensed. No agency has assessed the manufacturing, the purity, the sterility or the dose accuracy of the vial arriving at your door.
The phrase you will meet instead is “FDA-registered facility.” That describes the building. Registration is an administrative fact about a compounding pharmacy; it is not an approval, an inspection result or any statement about the product. A page that offers it as reassurance is substituting one thing for another, and the full regulatory picture is worth reading before a first purchase.
Oral precursors sit differently. NR is sold as a dietary supplement ingredient in the United States and has been the subject of New Dietary Ingredient notifications; NMN’s status as a lawful supplement ingredient is unresolved. Neither is FDA-approved as a drug either, but the supplement framework at least carries manufacturing requirements that a one-off compounded vial does not.
Route by route
Oral NR and NMN. The best-evidenced format, with dedicated randomized safety trials at doses well above what most products sell. Short duration is the limitation, not the findings.
Injection. No controlled safety trials. We searched PubMed in September 2026 for NAD⁺ administered subcutaneously or intramuscularly in humans and found no study reporting it. What exists instead is practice experience, which is not nothing but is also not a trial.
Intravenous. People receiving drips commonly report flushing, chest tightness, nausea and cramping during the infusion, managed by slowing the rate — practice reports rather than trial findings. There is one randomized, placebo-controlled trial of intravenous NAD⁺ we could locate, and it is instructive for a reason nobody advertises: it enrolled 180 adults with heart failure from ischemic cardiomyopathy and gave 10 mg a day for seven days, reporting a greater one-month improvement in ejection fraction than placebo (45.44 ± 8.55% vs 42.44 ± 9.09%, p = 0.024) [3]. Ten milligrams a day in supervised cardiac patients is not a safety dataset for a 250 mg wellness infusion.
A critical review of intravenous longevity therapy published in early 2026 — covering high-dose vitamins, glutathione and NAD⁺ together — concluded that placebo-controlled trials in this area are scarce and underpowered or conflicting, and that until adequately powered randomized trials exist the practice should be regarded as experimental rather than evidence-based [4]. That is a fair summary of the risk you are accepting, from clinicians rather than from us.
The three risks that are not about the molecule
Interactions. None of these trials set out to test what NAD⁺ or its precursors do alongside your other medications. That question is unanswered rather than answered reassuringly, which is why naming your full medication list to a clinician matters more here than with a product that has been through an approval process.
The unstated dose. Most injection sellers publish a monthly price and no milligram figure. You cannot assess the safety of a quantity you have not been told, and you cannot compare two products either — which is what our cost-per-milligram calculator exists to surface.
Self-administration. Home injection is a clinical procedure, and route and technique belong to the prescriber rather than to a product insert or a search result.
What a careful buyer does with this
Start with the format that has the trials. Oral precursors on the supplement board carry the safety evidence and cost a fraction of the alternatives. If you are being quoted an injectable or a drip, ask for the milligram figure and the schedule in writing, give a clinician your full medication list, and price the missing evidence in as a cost rather than treating silence as a clearance.
And if a seller tells you NAD⁺ is proven safe, ask which trial, in how many people, for how long, and by which route. Those four questions separate the formats faster than anything else, and what you should be paying becomes much clearer once you have the answers.